Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:615-629. Epub 2019 Mar 8.

GSK, Research and Development, Collegeville, PA, USA.

Background: Batefenterol is a novel bifunctional muscarinic antagonist β-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose-response of batefenterol and select a dose for Phase III development.

Patients And Methods: Patients aged ≥40 years with COPD and FEV ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, or 600 µg, placebo, or umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg once daily. The primary and secondary endpoints were weighted-mean FEV over 0-6 hours post-dose and trough FEV, analyzed by Bayesian and maximum likelihood estimation E of dose-response modeling, respectively, on day 42.

Results: In the intent-to-treat population (N=323), all batefenterol doses demonstrated statistically and clinically significant improvements from baseline vs placebo in the primary and secondary endpoints (191.1-292.8 and 182.2-244.8 mL, respectively), with a relatively flat dose-response. In the subgroup reversible to salbutamol, there were greater differences between batefenterol doses. Lung function improvements with batefenterol ≥150 µg were comparable with those with UMEC/VI. Batefenterol was well tolerated and no new safety signals were observed.

Conclusion: Batefenterol 300 µg may represent the optimal dose for Phase III studies.

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413745PMC
July 2019
4 Reads

Publication Analysis

Top Keywords

batefenterol
9
phase iii
8
dose phase
8
batefenterol doses
8
primary secondary
8
secondary endpoints
8
differences batefenterol
4
µg placebo
4
600 µg
4
150 300
4
300 600
4
µg
4
doses lung
4
placebo umeclidinium/vilanterol
4
µg daily
4
daily primary
4
625/25 µg
4
umec/vi 625/25
4
375 150
4
umeclidinium/vilanterol umec/vi
4

Similar Publications